Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3390
Abstract: Anti‐cancer drugs are approved typically on the basis of efficacy and safety as evaluated in phase III randomized trials (RCTs). Health‐related quality of life (HRQoL) is a direct measure of patient benefit, but is under‐reported.… read more here.
Keywords: phase; health related; iii randomized; phase iii ... See more keywords
Health‐related quality of life in stage III‐IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5183
Abstract: Cutaneous melanoma represents around over 90% of all melanoma. With more effective treatments able to extend patients' survival, health‐related quality of life (HRQOL) is increasingly becoming an important endpoint in cancer clinical trials. They are… read more here.
Keywords: iii randomized; randomized controlled; controlled trials; hrqol ... See more keywords
Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Medicine"
DOI: 10.1002/cam4.70235
Abstract: In a randomized phase II/III trial (JCOG1008), weekly cisplatin (40 mg/m2) was non‐inferior to 3‐weekly cisplatin (100 mg/m2) for postoperative high‐risk head and neck cancer. We investigated how acute kidney injury (AKI), a major dose‐limiting toxicity effect… read more here.
Keywords: phase iii; cancer; cisplatin; head neck ... See more keywords
Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta‐Epidemiological Analysis
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Medicine"
DOI: 10.1002/cam4.71097
Abstract: Blinding mitigates bias in randomized trials and may be especially crucial for surrogate endpoints, such as progression‐free survival (PFS). Here, we characterize utilization of and factors associated with blinding in Phase III oncology trials with… read more here.
Keywords: oncology; phase iii; blinding phase; randomized trials ... See more keywords
Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2535
Abstract: Selecting the right dose is a significant challenge in designing clinical development programs, especially for slowly progressing diseases lacking predictive biomarkers of efficacy that may require long‐term treatment to assess clinical benefit. Gantenerumab, a fully… read more here.
Keywords: gantenerumab; alzheimer disease; model; phase ... See more keywords
Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2601
Abstract: Tofacitinib is an oral small molecule JAK inhibitor for the treatment of ulcerative colitis. Relationships between plasma tofacitinib concentration and efficacy were characterized using exposure‐response (E‐R) models, with demographic and disease covariates evaluated as potential… read more here.
Keywords: maintenance; tofacitinib; efficacy; phase iii ... See more keywords
Comparisons of successful and failed Phase III trials of drugs and biologicals tested for mitigation of oral mucositis in patients being treated with radiotherapy with or without concomitant chemotherapy for cancers of the head and neck
Sign Up to like & getrecommendations! Published in 2024 at "Drug Development Research"
DOI: 10.1002/ddr.22188
Abstract: Oral mucositis (OM) remains a significant toxicity among patients being treated with radiotherapy (RT) alone or with concomitant chemotherapy (CRT) for cancers of the head and neck (HNC). Given its clinical significance as an unmet… read more here.
Keywords: phase iii; concomitant chemotherapy; oral mucositis; iii trials ... See more keywords
Reporting real‐life experience with drugs in lymphoma patients
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2284
Abstract: Carrying out clinical trials and reporting on these studies are essential requisites for drug development and approval. Phase IV studies are essential for the continuing monitoring of drugs. The differences are fundamental: the efficacy of… read more here.
Keywords: phase; drug; phase iii; real life ... See more keywords
ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R‐CHOP VS PLACEBO/R‐CHOP IN UNTREATED ABC‐TYPE DIFFUSE LARGE B‐CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2440
Abstract: OT01 ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R‐CHOP VS PLACEBO/ R‐CHOP IN UNTREATED ABC‐TYPE DIFFUSE LARGE B‐CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING A. Chiappella* | T.E. Witzig | U. Vitolo | R.… read more here.
Keywords: cell; hematology; oncology; phase iii ... See more keywords
Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Cancer"
DOI: 10.1002/ijc.31969
Abstract: In a formal prospective‐retrospective analysis of the phase III SBG0102 clinical trial randomizing metastatic breast cancer patients to gemcitabine‐docetaxel or to single agent docetaxel, patients with basal‐like tumors by PAM50 gene expression had significantly better… read more here.
Keywords: basal; phase iii; nestin inpp4b; breast cancer ... See more keywords
Reply to: Comments on “Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial”
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34219
Abstract: “ Effect of HIPEC according to HRD/ BRCA wt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial. In our study, we performed post hoc exploratory analysis of the effect… read more here.
Keywords: effect; hipec according; profile; hipec ... See more keywords